Ab&B Bio-Tech Partners with Walvax Unit to Take Flu Vaccine Overseas

Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) just unveiled an announcement.

Ab&B Bio-Tech has signed a strategic cooperation agreement with Walvax Hong Kong Limited to drive overseas registration, sales and commercialization of its core trivalent subunit influenza vaccine, Huierkangxin 3. Approved in January 2026 and currently the only trivalent subunit influenza vaccine in China indicated for people aged six months and above, the product will be the focal point of the partnership’s global push.

By leveraging Walvax Hong Kong’s international operating experience and established distribution networks, Ab&B Bio-Tech aims to accelerate entry into Southeast Asia, Latin America, the Middle East and other Southern Hemisphere markets. The agreement, which is not classified as a notifiable or connected transaction under Hong Kong listing rules and still awaits a definitive business contract, signals an effort to expand the company’s commercial footprint and enhance its competitive position in the global vaccine industry.

The most recent analyst rating on (HK:2627) stock is a Sell with a HK$47.00 price target. To see the full list of analyst forecasts on Ab&B Bio-Tech CO., LTD. JS Class H stock, see the HK:2627 Stock Forecast page.

More about Ab&B Bio-Tech CO., LTD. JS Class H

Ab&B Bio-Tech CO., LTD. JS is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccines, including its independently developed trivalent subunit influenza vaccine branded Huierkangxin 3. The company targets broad population coverage in the vaccine market, with products approved for use from infants aged six months through adults, positioning it within China’s expanding innovative vaccine segment.

Average Trading Volume: 470,368

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$24.39B

See more data about 2627 stock on TipRanks’ Stock Analysis page.